These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 10097753)

  • 1. [Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer].
    Matsumoto S; Kawasaki Y; Mikami M; Nakamoto M; Tokuyasu H; Kometani Y; Chikumi H; Hitsuda Y; Matsumoto Y; Sasaki T
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):535-8. PubMed ID: 10097753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
    Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
    Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Substance P and anticancer drug-induced emesis].
    Yamada T; Tanaka N; Yokoi K; Ishikawa N; Seya T; Horiba K; Kanazawa Y; Shirakawa T; Ohkawa K; Kudoh H; Koizumi M; Yoshioka M; Tajiri T
    Gan To Kagaku Ryoho; 2007 Jun; 34(6):903-6. PubMed ID: 17565253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
    Castejon AM; Paez X; Hernandez L; Cubeddu LX
    J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of efficacy of ramosetron orally disintegrating tablets and patient preference as to the dosage form in gynecological cancer chemotherapy].
    Nakayama S; Torii Y; Noda T
    Gan To Kagaku Ryoho; 2001 Aug; 28(8):1121-7. PubMed ID: 11525029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of oral versus intravenous ramosetron in prevention of acute cisplatin-induced emesis: a randomized controlled trial.
    Tantipalakorn C; Srisomboon J; Thienthong H; Pantusart A; Suprasert P; Saereesongkhun C; Eamtang S; Sutthichat A; Pautad N
    J Med Assoc Thai; 2004 Feb; 87(2):119-25. PubMed ID: 15061293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
    Taguchi T; Tsukamoto F; Watanabe T; Yoneda K; Takamura Y; Hojo S; Shiba E; Noguchi S
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1163-70. PubMed ID: 10431583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
    Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
    J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: relationship to nausea and vomiting.
    Hursti TJ; Börjeson S; Hellström PM; Avall-Lundqvist E; Stock S; Steineck G; Peterson C
    Scand J Gastroenterol; 2005 Jun; 40(6):654-61. PubMed ID: 16036525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
    Hayakawa T; Sato M; Konaka M; Makino A; Hirohata T; Totsu S; Wada Y; Sato H; Inotsume N; Fujita A; Sekine K
    Gan To Kagaku Ryoho; 2006 May; 33(5):633-8. PubMed ID: 16685162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
    Horichi N; Taguchi T; Furue H; Ikeda M; Tsukakoshi S
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):953-60. PubMed ID: 11478144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of granisetron, a 5-HT3 receptor antagonist, on 5-hydroxytryptamine (5-HT) release from the isolated ileum in a delayed-emesis rat model.
    Endo T; Hamaue N; Ihira E; Teramoto Y; Liu Y; Hirafuji M; Minami M
    Res Commun Mol Pathol Pharmacol; 2002; 111(1-4):55-68. PubMed ID: 14632314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
    Takenaka M; Okamoto Y; Ikeda K; Hashimoto R; Ueda T; Kurokawa N; Takagi T; Uejima E
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):403-7. PubMed ID: 17353632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.
    Warneck JB; Cheng FH; Barnes MJ; Mills JS; Montana JG; Naylor RJ; Ngan MP; Wai MK; Daiss JO; Tacke R; Rudd JA
    Toxicol Appl Pharmacol; 2008 Nov; 232(3):369-75. PubMed ID: 18675289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetic effect of ramosetron during hyperthermo-chemo-radiotherapy for esophageal cancer.
    Morita M; Kuwano H; Ohno S; Kitamura K; Sugimachi K
    Anticancer Res; 2000; 20(5C):3631-6. PubMed ID: 11268430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High plasma D-dimer level is associated with decreased survival in patients with lung cancer.
    Altiay G; Ciftci A; Demir M; Kocak Z; Sut N; Tabakoglu E; Hatipoglu ON; Caglar T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):494-8. PubMed ID: 17513096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.